Insmed Beheer

Beheer criteriumcontroles 2/4

De CEO Insmed is Will Lewis, benoemd in Sep2012, heeft een ambtstermijn van 12.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.41M, bestaande uit 7.5% salaris en 92.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.25% van de aandelen van het bedrijf, ter waarde € 29.03M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5 jaar en 10.5 jaar.

Belangrijke informatie

Will Lewis

Algemeen directeur

US$10.4m

Totale compensatie

Percentage CEO-salaris	7.5%
Dienstverband CEO	12.2yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	5yrs
Gemiddelde ambtstermijn bestuur	10.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Will Lewis's beloning veranderd ten opzichte van Insmed's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$864m
Jun 30 2024	n/a	n/a	-US$803m
Mar 31 2024	n/a	n/a	-US$747m
Dec 31 2023	US$10m	US$780k	-US$750m
Sep 30 2023	n/a	n/a	-US$724m
Jun 30 2023	n/a	n/a	-US$696m
Mar 31 2023	n/a	n/a	-US$547m
Dec 31 2022	US$8m	US$735k	-US$482m
Sep 30 2022	n/a	n/a	-US$434m
Jun 30 2022	n/a	n/a	-US$416m
Mar 31 2022	n/a	n/a	-US$438m
Dec 31 2021	US$7m	US$710k	-US$435m
Sep 30 2021	n/a	n/a	-US$424m
Jun 30 2021	n/a	n/a	-US$375m
Mar 31 2021	n/a	n/a	-US$319m
Dec 31 2020	US$6m	US$660k	-US$294m
Sep 30 2020	n/a	n/a	-US$245m
Jun 30 2020	n/a	n/a	-US$242m
Mar 31 2020	n/a	n/a	-US$247m
Dec 31 2019	US$7m	US$641k	-US$254m
Sep 30 2019	n/a	n/a	-US$293m
Jun 30 2019	n/a	n/a	-US$320m
Mar 31 2019	n/a	n/a	-US$330m
Dec 31 2018	US$6m	US$610k	-US$324m
Sep 30 2018	n/a	n/a	-US$298m
Jun 30 2018	n/a	n/a	-US$256m
Mar 31 2018	n/a	n/a	-US$224m
Dec 31 2017	US$4m	US$567k	-US$193m

Compensatie versus markt: De totale vergoeding ($USD 10.41M ) Will } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 5.00M ).

Compensatie versus inkomsten: De vergoeding van Will is gestegen terwijl het bedrijf verliesgevend is.

CEO

Will Lewis (55 yo)

12.2yrs

Tenure

US$10,411,260

Compensatie

Mr. William H. Lewis, also known as Will, J.D. M.B.A. serves as an Independent Chairman of Board of Directors of NewAmsterdam Pharma Company N.V. from January 2024. He has been Chief Executive Officer and...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
William Lewis	President	12.2yrs	US$10.41m	0.25% € 29.0m
Sara Bonstein	Chief Financial Officer	4.8yrs	US$4.56m	0.010% € 1.2m
Roger Adsett	Chief Operating Officer	5yrs	US$4.01m	0.036% € 4.1m
John Wise	Chief Commercial Officer	5yrs	US$3.89m	0.029% € 3.3m
Martina Flammer	Chief Medical Officer	4.9yrs	US$4.22m	0.0071% € 820.3k
Brian Kaspar	Chief Scientific Officer	no data	geen gegevens	geen gegevens
Eleanor Barisser	Associate Director of Investor Relations	no data	geen gegevens	geen gegevens
Michael Smith	Chief Legal Officer & Corporate Secretary	3.3yrs	geen gegevens	0.038% € 4.4m
Mandy Fahey	Executive Director of Corporate Communications	no data	geen gegevens	geen gegevens
S. Schaeffer	Chief People Strategy Officer	11.8yrs	US$2.66m	0.019% € 2.2m
Eugene Sullivan	Chief Product Strategy Officer	7.5yrs	US$1.69m	geen gegevens
Neil Hughes	GM & Head of Europe	5.4yrs	geen gegevens	geen gegevens

5.0yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IM8N is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
William Lewis	President	12.2yrs	US$10.41m	0.25% € 29.0m
David W. McGirr	Independent Director	11.1yrs	US$320.00k	0.048% € 5.5m
Melvin Sharoky	Independent Director	23.5yrs	US$312.50k	0.18% € 21.0m
Alfred Altomari	Independent Director	12.3yrs	US$320.00k	0.031% € 3.6m
David Brennan	Lead Independent Director	10.5yrs	US$345.00k	0.061% € 7.0m
Clarissa Desjardins	Independent Director	5yrs	US$315.00k	0.027% € 3.2m
Elizabeth Anderson	Independent Director	6yrs	US$310.00k	0.031% € 3.6m
Leo Lee	Independent Director	6.5yrs	US$317.50k	0.062% € 7.2m
Carol Schafer	Independent Director	4.6yrs	US$315.00k	0.025% € 2.9m

10.5yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IM8N zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.5 jaar).

Insmed Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Chief People Strategy Officer recently sold €628k worth of stock

Insufficient new directors

Insmed Incorporated, Annual General Meeting, May 13, 2024

Insufficient new directors

Insufficient new directors

Recent updates

Insmed Incorporated Reiterates earnings Guidance for the Year 2024

Third quarter 2024 earnings released: US$1.27 loss per share (vs US$1.11 loss in 3Q 2023)

Insmed Incorporated to Report Q3, 2024 Results on Oct 31, 2024

Insmed Incorporated Presents New Subgroup Analyses from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results

Insufficient new directors

Chief People Strategy Officer recently sold €628k worth of stock

Second quarter 2024 earnings released: US$1.94 loss per share (vs US$1.78 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Insmed Incorporated Reiterates Revenue Guidance for the Year 2024

Insmed Incorporated to Report Q2, 2024 Results on Aug 08, 2024

Insmed Incorporated Announces Additional Positive Results from the ASPEN Study

Insmed Incorporated has completed a Follow-on Equity Offering in the amount of $649.999989 million.

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 Arise Study of Arikayce in Patients with NTM Lung Disease at American Thoracic Society 2024 International Conference Plenary Session

Insufficient new directors

Insmed Incorporated to Report Q1, 2024 Results on May 09, 2024

Insmed Incorporated, Annual General Meeting, May 13, 2024

Insmed Incorporated to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

Insufficient new directors

Full year 2023 earnings released: US$5.34 loss per share (vs US$3.91 loss in FY 2022)

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insufficient new directors

Insmed Incorporated to Report Q4, 2023 Results on Feb 22, 2024

Insmed Incorporated Provides Sales Guidance for the Full Year 2023 and 2024

Third quarter 2023 earnings released: US$1.11 loss per share (vs US$1.09 loss in 3Q 2022)

Insmed Incorporated to Report Q3, 2023 Results on Oct 26, 2023

Insufficient new directors

Insmed Incorporated Announces Positive Topline Results from Phase 3 Arise Study of Arikayce® (Amikacin Liposome Inhalation Suspension) in Patients with Ntm Lung Disease Caused by Mac

Insmed Incorporated (NasdaqGS:INSM) acquired Adrestia Therapeutics Ltd.

Insmed Incorporated to Report Q2, 2023 Results on Aug 03, 2023

Insufficient new directors

Insmed Incorporated Presents Range of New Study Findings at American Thoracic Society 2023 International Conference

Senior VP recently sold €63k worth of stock

Insmed Incorporated Unveils New Research Platforms and Capabilities at Investor and Analyst Event

Insufficient new directors

Insmed Incorporated Provides Revenue Guidance for the Full-Year 2023

Insufficient new directors

Full year 2022 earnings released: US$3.91 loss per share (vs US$3.88 loss in FY 2021)

Insmed Incorporated to Report Q4, 2022 Results on Feb 23, 2023

Insufficient new directors

Insufficient new directors

Chief Operating Officer recently sold €217k worth of stock

Independent Director recently bought €805k worth of stock

Third quarter 2022 earnings released: US$1.09 loss per share (vs US$0.96 loss in 3Q 2021)

Insmed Incorporated Provides Revenue Guidance for the Year 2022

Insmed Incorporated announced that it expects to receive $625 million in funding

Insmed Incorporated to Report Q3, 2022 Results on Oct 27, 2022

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$1.07 loss in 2Q 2021)

Insmed Incorporated Reiterates Revenue Guidance for the Full Year 2022

Insmed Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Insmed Incorporated Names Drayton Wise as Chief Commercial Officer

Independent Director recently bought €326k worth of stock

First quarter 2022 earnings released: US$0.80 loss per share (vs US$0.89 loss in 1Q 2021)

Insmed Incorporated to Report Q1, 2022 Results on May 05, 2022

Insmed Incorporated, Annual General Meeting, May 11, 2022

Insmed Incorporated Provides Earnings Guidance for the Full Year 2022

Insmed Incorporated to Report Q4, 2021 Results on Feb 17, 2022

High number of new directors

High number of new directors

Insmed Incorporated Unable to Provides Revenue Guidance Due to Covid

Insmed Incorporated has completed a Follow-on Equity Offering in the amount of $250 million.

First quarter 2021 earnings released: US$0.89 loss per share (vs US$0.74 loss in 1Q 2020)

Independent Director recently bought €83k worth of stock

Full year 2020 earnings released: US$3.01 loss per share (vs US$3.01 loss in FY 2019)

Revenue misses expectations

Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP)

Insmed Incorporated to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €36.40

New 90-day high: €34.20